{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:15:17Z","timestamp":1763748917062},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,15]]},"DOI":"10.7759\/cureus.40448","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:38:52Z","timestamp":1686821932000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals with Type 2 Diabetes: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Huma","family":"Irfan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namratha","family":"Pallipamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvedha S","family":"Thiagaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Twisha S","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathish","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin randomized controlled trial","volume":"43","author":"Garvey WT","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, et al.. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin randomized controlled trial. Diabetes Care. 2020, 43:1085-93. 10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13775","article-title":"Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type\u20092 diabetes: A systematic review and meta-analysis","volume":"13","author":"Duan K","year":"2022","unstructured":"Duan K, Yan X, Gao Z, Hou Y, Lv X, Song G. Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type\u20092 diabetes: A systematic review and meta-analysis. J Diabetes Investig. 2022, 13:1149-60. 10.1111\/jdi.13775","journal-title":"J Diabetes Investig"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14193","article-title":"Educational weight loss interventions in obese and overweight adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Maula A","year":"2020","unstructured":"Maula A, Kai J, Woolley AK, et al.. Educational weight loss interventions in obese and overweight adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2020, 37:623-35. 10.1111\/dme.14193","journal-title":"Diabet Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073451","article-title":"Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: the impact of pharmacological properties and genetic factors","volume":"23","author":"Klen J","year":"2022","unstructured":"Klen J, Dol\u017ean V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: the impact of pharmacological properties and genetic factors. Int J Mol Sci. 2022, 23:3451. 10.3390\/ijms23073451","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0020","article-title":"Optimizing the use of glucagon-like peptide 1 receptor agonists in type 2 diabetes: executive summary","volume":"40","author":"Anderson J","year":"2022","unstructured":"Anderson J, Gavin JR 3rd, Kruger DF, Miller E. Optimizing the use of glucagon-like peptide 1 receptor agonists in type 2 diabetes: executive summary. Clin Diabetes. 2022, 40:265-9. 10.2337\/cd22-0020","journal-title":"Clin Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-019-0348-6","article-title":"Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial","volume":"44","author":"Tronieri JS","year":"2020","unstructured":"Tronieri JS, Wadden TA, Walsh O, et al.. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. Int J Obes (Lond). 2020, 44:353-61. 10.1038\/s41366-019-0348-6","journal-title":"Int J Obes (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(22)60196-1","article-title":"Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor\/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity","volume":"20","author":"Li Q","year":"2022","unstructured":"Li Q, Yang Q, Han J, Liu X, Fu J, Yin J. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor\/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity. Chin J Nat Med. 2022, 20:863-72. 10.1016\/S1875-5364(22)60196-1","journal-title":"Chin J Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15860","article-title":"A GLP-1\/glucagon (GCG)\/CCK(2) receptors tri-agonist provides new therapy for obesity and diabetes","volume":"179","author":"Zhao S","year":"2022","unstructured":"Zhao S, Yan Z, Du Y, et al.. A GLP-1\/glucagon (GCG)\/CCK(2) receptors tri-agonist provides new therapy for obesity and diabetes. Br J Pharmacol. 2022, 179:4360-77. 10.1111\/bph.15860","journal-title":"Br J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13824","article-title":"Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study","volume":"21","author":"Pratley RE","year":"2019","unstructured":"Pratley RE, Kang J, Trautmann ME, et al.. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obes Metab. 2019, 21:2429-39. 10.1111\/dom.13824","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3123-1","article-title":"EndoBarrier\u00ae: a safe and effective novel treatment for obesity and type 2 diabetes?","volume":"28","author":"Patel N","year":"2018","unstructured":"Patel N, Mohanaruban A, Ashrafian H, et al.. EndoBarrier\u00ae: a safe and effective novel treatment for obesity and type 2 diabetes?. Obes Surg. 2018, 28:1980-9. 10.1007\/s11695-018-3123-1","journal-title":"Obes Surg"},{"key":"ref11","article-title":"Semaglutide: an expedition on last approved glucagon-like peptide-1 analog of past decade","volume":"13","author":"Rai AK","year":"2021","unstructured":"Rai AK, Roy K, Das R, Verma SK. Semaglutide: an expedition on last approved glucagon-like peptide-1 analog of past decade. Pharmaspire. 2021, 13:151-6.","journal-title":"Pharmaspire"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1573399814666180608074510","article-title":"Pathophysiology of type 2 diabetes in children and adolescents","volume":"16","author":"Valaiyapathi B","year":"2020","unstructured":"Valaiyapathi B, Gower B, Ashraf AP. Pathophysiology of type 2 diabetes in children and adolescents. Curr Diabetes Rev. 2020, 16:220-9. 10.2174\/1573399814666180608074510","journal-title":"Curr Diabetes Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.11.029","article-title":"Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes","volume":"166","author":"Elder DA","year":"2015","unstructured":"Elder DA, Hornung LN, Herbers PM, Prigeon R, Woo JG, D'Alessio DA. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. J Pediatr. 2015, 166:672-8. 10.1016\/j.jpeds.2014.11.029","journal-title":"J Pediatr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/121585-role-of-glucagon-like-peptide-1-receptor-agonists-on-the-weight-loss-of-individuals-with-type-2-diabetes-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:35Z","timestamp":1707508955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/121585-role-of-glucagon-like-peptide-1-receptor-agonists-on-the-weight-loss-of-individuals-with-type-2-diabetes-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.40448","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}